Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
346 Leser
Artikel bewerten:
(1)

Mercury Medical Inc.: Bleep, LLC Signs Distribution Agreement with Mercury Medical Expanding its Acute Care Commercial Capability in the U.S.

Mercury Medical announces Bleep, LLC partnership.

CLEARWATER, FL / ACCESSWIRE / July 12, 2021 / Pressure ulcers not only drive high cost for Acute Care centers, but also drive patient dissatisfaction. Traditional CPAP masks and pressure ulcers are commonly related to headgear/straps on PAP mask being too loose or too tight. Mask and nasal pillow pressure and friction is the top cause. "The average 300-bed acute facility with a 2.4% incidence rate spends $14 million a year on pressure ulcer prevention and treatment. The Centers for Medicare and Medicaid Services (CMS) spends $22 billion a year on pressure ulcers as a secondary diagnosis, according to a recent report by healthcare finance news."

DreamPort® by Bleep is the only clinically proven not to leak PAP solution that has no headgear/straps, and the only fully made in USA product, addressing the main concerns of Acute Care centers and de-risking supply.

Bleep is excited to announce expansion of its' acute care focus in the US market by entering into a nationwide distribution agreement with Mercury Medical. Mercury is a leading US healthcare specialty organization known for providing cutting-edge technology in the acute care respiratory market segment - a philosophy that is fully in line with Bleep.

The Bleep sleep solution uses hypoallergenic, BPA, latex, and corn-free medical-grade adhesive strips to hold the DreamPorts in place on the nose for optimized comfort. Over 70% of CPAP complaints are related to bulky headgear and uncomfortable straps - the DreamPort Sleep Solution fits the exact shape of the nose, eliminating headgear, skin tears, leaks, and discomfort. DreamPorts are easy to apply and won't leave marks on the face at the end of the night. This Sleep Solution won't constrict movement allowing patients to sleep comfortably on their side, back or in the prone position. DreamPort also decreases claustrophobia.

John Gargaro MD, President, and CEO at Mercury Medical, states: "Mercury Medical believes that Bleep is a long overdue superior solution designed to improve sleep apnea patient comfort by eliminating common problems of mask leaks and skin breakdown. As a company, Mercury Medical has a rich experience in introducing innovative, clinically differentiated medical devices to market. We are extremely pleased to partner with Bleep in this endeavor to advance practices in the sleep apnea realm."

"Mercury Medical is an outstanding partner to both Acute Care centers and to the VA, focused on providing innovative solutions to drive health outcomes, compliance and improved cost. Bleep looks forward to providing Mercury Medical with DreamPort®, the only No Leak sleep solution on the market, driving value for patients, providers and Acute Care Centers," states Bleep, LLC CEO, Rebecca Holland New.

About Bleep Sleep (bleepsleep.com)
Bleep Sleep Solutions, based in Chapel Hill, NC is a sleep solution company focused on improving sleep and sleep related health outcomes. The DreamPort® is a one-size-fits-all, single SKU CPAP solution with zero headgear. It has been clinically proven not to leak, eliminates mask lines and facial irritation. It is compatible with all CPAP machines and covered by all major insurance plans. DreamPort is FDA cleared, and manufactured entirely in the United States. DreamPort provides respiratory support for patients who need continuous positive air pressure solution, such as sleep apnea.

About Mercury Medical

Mercury Medical is dedicated to delivering clinically differentiated critical care technology that saves lives throughout the world. For over 55 years clinicians have relied on Mercury Medical as their resource for bringing a legacy of innovative products to critical care areas of neonatal, anesthesia, respiratory and emergency markets in more than 58 countries. Mercury Medical's high-quality standards include ISO 13485 and ISO 9001 certifications.

For more information visit www.mercurymed.com

CONTACT:
D. Olson
Mercury Medical
727-573-4980
www.mercurymed.com

SOURCE: Mercury Medical Inc.



View source version on accesswire.com:
https://www.accesswire.com/655107/Bleep-LLC-Signs-Distribution-Agreement-with-Mercury-Medical-Expanding-its-Acute-Care-Commercial-Capability-in-the-US

© 2021 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.